New anxiety, low mood, poor sleep, or brain fog in midlife may involve perimenopause—or something else. The goal is not to blame every symptom on hormones. It is to understand the pattern and make room for a careful evaluation.

What this guide covers — and what it deliberately does not. It covers new mental-health changes during perimenopause, the medical and psychiatric problems that can look similar, and the limits of testing and treatment. PMDD diagnosis belongs to the menstrual-cycle and PMDD guide. Full insomnia and sleep-disorder treatment belongs to the women’s sleep guide. A full adult ADHD evaluation belongs to the ADHD in women guide.

A weighted sounding line drops from a small boat through dark night water to a seafloor made of five different materials, then the seafloor becomes a chart where a run of amber marks draws one contour — the graphic teaches that no single hormone test can name the cause of new midlife anxiety, low mood, poor sleep or brain fog, while a dated pattern log can. Read top to bottom. Five look-alike causes are named: thyroid disease or low iron; sleep apnea, restless legs or chronic insomnia; depression, anxiety or panic; medicines and substances; and perimenopause itself, often alongside one of the others. Colour is never the only cue — every cause carries its own printed label. — No single hormone test can name the cause. A dated log of cycle, sleep, mood, and function shows what one number cannot. Tap the image to read it full size.

The moment something feels unfamiliar

Maya wakes at 3:17 a.m. again. Her chest feels tight, although nothing frightening happened that day. She has started losing words in meetings. Her periods arrive on a schedule she no longer recognizes.

At 44, she wonders whether she is becoming “bad at coping.” She also wonders whether this is perimenopause. Both questions feel too large at three in the morning.

Fictional composite; not a real patient.

This kind of change deserves more than a slogan. Perimenopause can affect sleep, hot flashes, mood, and mental stamina. It can also arrive beside depression, panic, thyroid disease, iron deficiency, sleep apnea, medication effects, or a demanding season of life.

The useful question is rarely, “Is this hormones or mental health?” A better question is, “What changed, when did it change, and what else was happening?”

That question leaves room for more than one answer. It also protects you from two common mistakes: dismissing real symptoms as “just stress,” or treating every midlife change as proof of a hormone problem.

What perimenopause is—and what it cannot tell you

Perimenopause is a stage of reproductive aging. Clinicians identify it mainly through changes in menstrual patterns and symptoms over time. A widely used staging system is called STRAW+10.[1]

The stage does not begin on one universal birthday. It does not look the same for every person. Cycles may become shorter, longer, skipped, heavier, or simply less predictable.

Natural menopause is recognized after 12 months without a period when another cause is not present.[9] Perimenopause includes the transition leading toward that point and the first year afterward.

For otherwise healthy people older than 45, current NICE guidance uses symptoms and cycle history rather than routine hormone testing.[2] A single FSH, estradiol, or AMH result cannot show that perimenopause caused anxiety or depression.

Testing can still matter in selected situations. A clinician may use FSH when symptoms suggest menopause between ages 40 and 45, or when ovarian insufficiency is suspected before 40. Hormonal contraception, hysterectomy, irregular cycles, and cancer treatment can make staging harder.

This is why a mail-order “hormone balance” panel cannot replace a medical history. Hormone levels can move across a cycle and across the transition. A number without timing, symptoms, treatment history, and context can sound more certain than it is.

Why mood can change without one simple cause

The menopausal transition appears to be a window of increased depression vulnerability for some people. A 2024 review pooled seven longitudinal studies with 9,141 participants. Perimenopause was associated with about 40% higher odds of depressive symptoms or disorder than premenopause.[3]

That is a population association, not a prediction for you. Most people do not inevitably develop depression. The same review did not find a significant postmenopause-versus-premenopause difference.

Past depression matters. So can a family history, stressful events, sleep loss, hot flashes, pain, illness, and limited support. These influences may overlap rather than compete.[4]

A careful explanation uses the idea of sensitivity to change. In a susceptible person, shifts in reproductive hormones may interact with brain systems, sleep, and stress. Research does not support a routine story in which one “low” hormone value directly explains one person’s mood.

The indirect pathways can be powerful. Night sweats can break sleep into fragments. Poor sleep can increase irritability and make worry harder to regulate. Migraine, heavy bleeding, caregiving, work strain, and relationship stress can add another layer.

This is more complex than “estrogen drops, so serotonin drops.” It is also more hopeful. A complex picture offers several places to intervene: the mood disorder, the sleep problem, the hot flashes, the medical cause, or the load around you.

Anxiety, panic, irritability, and recurrence

Some people notice anxiety for the first time during the transition. Others feel an old pattern return. It may show up as dread on waking, physical tension, panic-like surges, rumination, irritability, or a shorter emotional fuse.

The anxiety evidence is less settled than the depression evidence. In the SWAN study, people with low anxiety at baseline were more likely to develop a high-anxiety symptom pattern during transition stages.[5] The study measured a symptom cluster, not a formal diagnosis of generalized anxiety or panic disorder.

That distinction matters. Perimenopause can be part of the timing without being the whole diagnosis. A panic attack still deserves a panic-focused assessment. Persistent worry may meet criteria for an anxiety disorder. A period of unusually high energy, very little need for sleep, impulsive behavior, or racing thoughts may point toward hypomania, mania, or mixed symptoms.

Premenstrual worsening also needs its own timeline. Symptoms that appear mainly before bleeding and then clear may suggest PMDD. Symptoms present all month but worse before bleeding may be premenstrual exacerbation of another condition.

The aim is not to collect labels. It is to identify which pattern best explains the symptoms and which treatment has evidence for that pattern.

Brain fog and sleep: real symptoms, careful boundaries

“Brain fog” is not one medical test result. People use it for word-finding trouble, distractibility, slower recall, reduced mental stamina, or feeling less sharp under pressure.

An updated review of 26 articles and 9,428 participants found mixed cognitive results across perimenopause.[6] Menopause stage and study methods helped explain some differences. Earlier SWAN work found a small, temporary learning change during the transition, followed by recovery.[7]

This does not mean the experience is imaginary. Subjective cognitive strain can be painful even when testing shows a small average change. Sleep loss, anxiety, depression, hot flashes, pain, medication effects, and constant multitasking can all affect attention.

It also does not mean every memory change is perimenopause. Sudden confusion, trouble speaking, one-sided weakness, a severe new headache, seizure, or rapidly worsening function needs prompt medical care.

Sleep deserves its own questions. Are hot flashes waking you? Is worry keeping you awake? Do you snore, gasp, wake with headaches, or feel sleepy while driving? Do your legs feel driven to move at night?

Chronic insomnia, sleep apnea, and restless legs are treatable problems. They should not disappear under a hormone label. Full sleep treatment is covered in the women’s sleep guide; this page keeps the focus on recognizing overlap.

When not to wait

Some changes need urgent assessment, even when they happen during perimenopause.

Call 911 or go to the nearest emergency department for immediate danger, violent intent, psychosis, severe confusion, a sudden neurologic change, medical instability, or inability to maintain safety. Suicidal intent or a plan also needs emergency help. Do not wait for a hormone appointment or another cycle.

Seek prompt medical care for heavy or unexplained bleeding, bleeding after menopause, fainting, chest pain, or severe shortness of breath. These are not symptoms to sort out with a tracker.

Mania can also be missed when sleep is already poor. Warning signs include needing very little sleep while feeling energized, rapidly increasing activity, risky behavior, unusual confidence, agitation, or losing touch with reality.[8]

If thoughts of suicide are present without immediate danger, contact a clinician promptly or call or text 988. The complete crisis and local-resource list appears near the end of this article.

Urgent care is not an overreaction. It is a way to protect time, safety, and treatment options while the cause is being clarified.

What else can look like perimenopause

Midlife symptoms often cross medical specialties. A good evaluation keeps the list broad enough to be safe and focused enough to be useful.

Possible psychiatric explanations include major depression, generalized anxiety, panic disorder, bipolar disorder, PTSD, grief, ADHD, eating disorders, and substance effects. A past episode can return during a stressful transition.

Pregnancy is still possible before menopause. PMDD and premenstrual exacerbation can also become harder to recognize when cycles change.

Medical mimics include thyroid disease, anemia or iron deficiency, sleep apnea, restless legs, migraine, chronic pain, seizure disorders, and medication effects. Alcohol, cannabis, sedatives, stimulants, and heavy caffeine use can change sleep and anxiety.

Not every person needs every laboratory test. A clinician may order a pregnancy test, CBC, ferritin, thyroid testing, or another study when the history points that way. Heavy bleeding and fatigue make iron status more relevant. Snoring and daytime sleepiness make sleep evaluation more relevant.

The same rule applies to psychiatric screening. A symptom questionnaire can help measure severity. It cannot decide whether the cause is perimenopause, bipolar disorder, trauma, a sleep condition, or several things at once.

What a careful evaluation looks like

A useful appointment begins with a timeline. Bring changes in cycle length, flow, hot flashes, sleep, mood, anxiety, attention, pain, and function.

The clinician should ask about past depression, anxiety, panic, trauma, ADHD symptoms, substance use, and family history. A lifetime history of hypomania or mania is especially important before an antidepressant plan.[8]

Medication and supplement timing matters. Note when a hormone, contraceptive, steroid, thyroid medicine, stimulant, sedative, or supplement started or changed. Include alcohol, cannabis, nicotine, and caffeine.

The physical context matters too. Discuss pregnancy possibility, bleeding, migraine, pain, snoring, restless legs, weight change, palpitations, and neurologic symptoms. Testing should follow those clues rather than become a universal panel.

Finally, describe function in plain language. Are you missing work? Taking twice as long? Withdrawing from people? Making mistakes? Unable to rest? Feeling unsafe?

The result may be one diagnosis, several conditions, or a period of distress that does not meet a disorder threshold. Each deserves an honest plan. The evaluation is not successful only when it produces a single hormone explanation.

Treat the condition in front of you

If you meet criteria for depression or an anxiety disorder, evidence-based psychiatric care remains central. Psychotherapy, medication when appropriate, or both may help.[4]

Treatment should reflect your history and preferences. It should also consider pregnancy plans, prior response, side effects, drug interactions, and bipolar risk. No medication schedule belongs in a general article.

Therapy can address depressive withdrawal, worry, panic, grief, identity change, caregiving strain, and boundaries. Menopause-focused CBT and mindfulness programs may offer small improvements in mood or anxiety, although studies are mixed and long-term data are limited.[10]

Sleep treatment may be part of the plan. Multicomponent CBT for insomnia is strongly recommended for chronic insomnia in adults.[11] Sleep apnea or restless legs requires a different approach.

Treating hot flashes can improve sleep and reduce distress. That does not automatically make every hot-flash medicine an antidepressant. Treatment targets should stay clear.

The plan may therefore have several parts: psychotherapy for panic, iron treatment for documented deficiency, sleep care for apnea, and menopause treatment for hot flashes. Coordinated care is often more useful than searching for one perfect label.

Where hormone therapy fits—and where it does not

Menopausal hormone therapy is the most effective treatment for bothersome vasomotor symptoms. For many healthy, symptomatic people younger than 60 or within 10 years of menopause onset, benefits may outweigh risks after individual review.[12]

That sentence has boundaries. The exact product and route matter. So do uterus status, unexplained bleeding, clotting history, cardiovascular and liver disease, migraine context, and breast or endometrial cancer history.

Systemic estrogen usually requires endometrial protection when a uterus is present. Local vaginal treatment and systemic treatment have different goals and exposures. Oral and transdermal routes are not interchangeable risk statements.

MHT may improve mood when hot flashes and sleep improve. Small trials also suggest that specific estradiol regimens may help selected perimenopausal depression or prevention populations. In one 12-month prevention trial, clinically significant depressive symptoms developed in 32.3% of the placebo group and 17.3% of the active-treatment group.[13]

That trial does not mean everyone should take hormones to prevent depression. Estrogen is not FDA-approved as a universal antidepressant. MHT is not an ADHD treatment, cognitive enhancer, or dementia-prevention treatment.

Compounded “bioidentical” products should not be routine when an FDA-approved option can meet the need.[14] “Natural” does not prove safer, and saliva-based balancing plans are not validated psychiatric care.

On February 12, 2026, FDA approved labeling changes for six products: Prometrium, Divigel, Cenestin, Enjuvia, Estring, and Bijuva.[15,16] The action did not cover every MHT product and did not declare hormone therapy risk-free. The current label for the exact product remains controlling.

Nonhormonal hot-flash options also exist. Fezolinetant carries a current FDA warning about rare serious liver injury and requires label-based review and monitoring.[17] Hot-flash benefit should not be described as proven mood treatment.

POI, surgery, and cancer treatment need a different map

Premature ovarian insufficiency means loss of usual ovarian function before age 40. It can affect fertility, bone, cardiovascular, sexual, and mental health. Diagnosis and treatment differ from routine natural perimenopause.[18]

Removing both ovaries causes an abrupt surgical menopause. Chemotherapy, radiation, and some other treatments can also change ovarian function. The speed, age, medical reason, and cancer history shape the risks and choices.

These situations can carry grief, fertility loss, body changes, and fear about long-term health. Mental-health support belongs in the care plan, not as an afterthought.

Hormone treatment may be recommended differently in POI than in typical-age menopause. A hormone-sensitive cancer or clotting history can also change the plan. General social-media rules are unsafe in both directions: hormones are not always forbidden, and they are not always appropriate.

If symptoms began after ovarian surgery or cancer treatment, name that timing clearly. Ask whether gynecology, oncology, primary care, and mental-health clinicians need to coordinate.

A pattern log to bring to an appointment

This tool helps organize observations. It does not diagnose perimenopause or a mental-health condition.

Date	Cycle or bleeding change	Hot flashes or night sweats	Sleep	Mood, anxiety, irritability	Focus or memory	Medicine or hormone change	Caffeine, alcohol, other substances	Stress, pain, illness, caregiving	Effect on work, home, safety

Complete one brief line each day or whenever symptoms change. Bring the pattern—not a conclusion—to an appointment.

Privacy note: The safest default is to print this page or save a local copy on a device only you control. NPFady should not collect cycle details, psychiatric symptoms, or safety responses through a web form without a documented privacy and deletion process. If someone may monitor your device, use a safer device or do not save sensitive details.

Stop tracking and seek urgent care for suicidal intent, inability to stay safe, psychosis, mania, sudden confusion, weakness, trouble speaking, a severe new headache, or heavy unexplained bleeding.

The next step can be smaller than a verdict

You do not need to arrive at an appointment knowing the cause. You need a clear account of what changed and how it affects your life.

Sometimes the answer includes perimenopause and a separate condition. Sometimes better sleep or hot-flash treatment reduces the strain. Sometimes a depressive or anxiety disorder needs direct care.

The important shift is from self-blame to investigation. A changing cycle can be a clue. It should never become a reason to dismiss your mind, your body, or a symptom that needs attention.

Before the visit, choose two or three examples that show the change clearly. Name what happened, when it began, and what you could no longer do in the usual way. Bring your medicine list and the rough timing of cycle, sleep, or hot-flash changes. If the appointment is short, begin with the symptom that most affects safety or daily life. You can ask what the clinician is considering, what needs to be ruled out, and when the plan will be reviewed. A useful visit does not require a perfect diary or the right medical words.

You deserve a plan that takes your whole health seriously.

The rest of this series

Ten guides on women’s mental health, written to be read in any order. Each one owns its own question, so none of them repeats another.

Education disclaimer

This article is for general education. It cannot diagnose you, replace an evaluation, or give personal medical advice. Reading NPFady.com does not create a clinician-patient relationship. Do not start, stop, or change medication or hormone treatment without the clinician who knows your history.

References

Harlow SD, Gass M, Hall JE, et al. Executive summary of the Stages of Reproductive Aging Workshop +10: addressing the unfinished agenda of staging reproductive aging. J Clin Endocrinol Metab. 2012;97:1159–1168. doi:10.1210/jc.2011-3362. PMID: 22344196. PMCID: PMC3319184. https://pubmed.ncbi.nlm.nih.gov/22344196/
National Institute for Health and Care Excellence. Menopause: identification and management (NG23). Updated November 7, 2024. https://www.nice.org.uk/guidance/ng23. Accessed 2026-08-15.
Badawy Y, et al. The risk of depression in the menopausal stages: a systematic review and meta-analysis. J Affect Disord. 2024;357:126–133. doi:10.1016/j.jad.2024.04.041. PMID: 38642901. https://pubmed.ncbi.nlm.nih.gov/38642901/
Maki PM, Kornstein SG, Joffe H, et al. Guidelines for the evaluation and treatment of perimenopausal depression: summary and recommendations. J Womens Health (Larchmt). 2019;28:117–134. doi:10.1089/jwh.2018.27099.mensocrec. PMID: 30182804. https://pubmed.ncbi.nlm.nih.gov/30182804/
Bromberger JT, Kravitz HM, Chang YF, et al. Does risk for anxiety increase during the menopausal transition? Study of Women’s Health Across the Nation. Menopause. 2013;20:488–495. doi:10.1097/GME.0b013e3182730599. PMID: 23615639. PMCID: PMC3641149. https://pmc.ncbi.nlm.nih.gov/articles/PMC3641149/
Bangle A, Williams DM, Walters J, Nguyen L. Cognitive functioning in perimenopause: an updated systematic review and meta-analysis. Psychol Aging. Published online 2025; volume publication 2026. doi:10.1037/pag0000946. PMID: 41066270. https://pubmed.ncbi.nlm.nih.gov/41066270/
Greendale GA, Huang MH, Wight RG, et al. Effects of the menopause transition and hormone use on cognitive performance in midlife women. Neurology. 2009;72:1850–1857. doi:10.1212/WNL.0b013e3181a71193. PMID: 19470968. PMCID: PMC2690984. https://pubmed.ncbi.nlm.nih.gov/19470968/
U.S. Department of Veterans Affairs and Department of Defense. VA/DoD Clinical Practice Guideline for Management of Bipolar Disorder. 2023. https://www.healthquality.va.gov/guidelines/mh/bd/. Accessed 2026-08-15.
Santoro N, Roeca C, Peters BA, Neal-Perry G. The menopause transition: signs, symptoms, and management options. J Clin Endocrinol Metab. 2021;106:1–15. doi:10.1210/clinem/dgaa764. PMID: 33095879. https://pubmed.ncbi.nlm.nih.gov/33095879/
Spector A, et al. The effectiveness of psychosocial interventions on non-physiological symptoms of menopause: a systematic review and meta-analysis. J Affect Disord. 2024;352:460–472. doi:10.1016/j.jad.2024.02.048. PMID: 38364979. https://pubmed.ncbi.nlm.nih.gov/38364979/
Edinger JD, Arnedt JT, Bertisch SM, et al. Behavioral and psychological treatments for chronic insomnia disorder in adults: an American Academy of Sleep Medicine clinical practice guideline. J Clin Sleep Med. 2021;17:255–262. doi:10.5664/jcsm.8986. PMID: 33164742. PMCID: PMC7853203. https://pmc.ncbi.nlm.nih.gov/articles/PMC7853203/
The North American Menopause Society Advisory Panel. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022;29:767–794. doi:10.1097/GME.0000000000002028. PMID: 35797481. https://pubmed.ncbi.nlm.nih.gov/35797481/
Gordon JL, Rubinow DR, Eisenlohr-Moul TA, et al. Efficacy of transdermal estradiol and micronized progesterone in the prevention of depressive symptoms in the menopause transition: a randomized clinical trial. JAMA Psychiatry. 2018;75:149–157. doi:10.1001/jamapsychiatry.2017.3998. PMID: 29322164. PMCID: PMC5838629. https://pmc.ncbi.nlm.nih.gov/articles/PMC5838629/
American College of Obstetricians and Gynecologists. Compounded bioidentical menopausal hormone therapy: ACOG Clinical Consensus No. 6. Obstet Gynecol. 2023. doi:10.1097/AOG.0000000000005395. PMID: 37856860. https://pubmed.ncbi.nlm.nih.gov/37856860/
U.S. Food and Drug Administration. FDA approves labeling changes to menopausal hormone therapy products. February 12, 2026. https://www.fda.gov/news-events/press-announcements/fda-approves-labeling-changes-menopausal-hormone-therapy-products. Accessed 2026-08-15.
U.S. Food and Drug Administration. Menopausal hormone therapies with updated prescribing information. February 12, 2026. https://www.fda.gov/drugs/drug-safety-and-availability/menopausal-hormone-therapies-updated-prescribing-information. Accessed 2026-08-15.
U.S. Food and Drug Administration. FDA adds warning about rare occurrence of serious liver injury with use of Veozah (fezolinetant) for hot flashes due to menopause. 2024. https://www.fda.gov/drugs/drug-safety-communications/fda-adds-warning-about-rare-occurrence-serious-liver-injury-use-veozah-fezolinetant-hot-flashes-due. Accessed 2026-08-15.
European Society of Human Reproduction and Embryology, American Society for Reproductive Medicine, CRE-WHiRL, and International Menopause Society. Evidence-based guideline: premature ovarian insufficiency. 2024. https://www.asrm.org/practice-guidance/practice-committee-documents/evidence-based-guideline-premature-ovarian-insufficiency—2024/. Accessed 2026-08-15.

If you or someone you know is in crisis

Call 911 or go to your nearest emergency room for any life-threatening emergency.

988 Suicide & Crisis Lifeline — call or text 988, available 24/7. En español: marque 988 y oprima 2. Veterans: 988 and press 1, or text 838255.

Crisis Text Line — text HOME to 741741.

The Trevor Project (crisis support for LGBTQ+ young people) — call 1-866-488-7386, or text START to 678-678.

National Sexual Assault Hotline (RAINN) — call 1-800-656-HOPE (4673) or text HOPE to 64673; free, confidential, 24/7. Online chat at RAINN.org/hotline.

National Domestic Violence Hotline — call 1-800-799-SAFE (7233) or text START to 88788; 24/7, help in 200+ languages. Online chat at TheHotline.org. If your phone or computer may be monitored, calling from a safer device is an option.

Riverside County — Inland SoCal Crisis Helpline 951-686-HELP (4357), 24/7 (Inland SoCal United Way / 211+, in partnership with RUHS-BH); Community Access, Referral, Evaluation and Support (CARES) Line 800-499-3008, 24/7.

San Bernardino County — Access Unit (Behavioral Health Helpline) 888-743-1478, 24/7; Mobile Crisis/CCRT 800-398-0018 (24/7, all ages) or text 909-420-0560. Arrowhead Regional Medical Center (ARMC) has a dedicated walk-in adolescent psychiatric ER (ages 13–17).

Children under 13 — call 911 for immediate danger, contact your county's mobile crisis team (they respond to all ages), or go to the nearest pediatric emergency room.

California Peer-Run Warm Line (non-crisis — someone to talk to) — call or text 1-855-600-WARM (9276); daytime and evening hours, not a 24/7 line.

NP Fady (non-emergency) — for routine scheduling or questions, call (909) 707-6261. This line is not monitored for emergencies.

“I Don’t Feel Like Myself Anymore”: The Mental Health Changes Women Aren’t Warned About in Perimenopause